CSBRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
CHAMPIONS ONCOLOGY, INC.
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 11, 2026
$4.69−0.01 (-0.21%)
Close on Oct 19, 2026
- Market cap
- $65.18M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.80 (−27.70%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
CHAMPIONS ONCOLOGY, INC. grew revenue 6.7% to $60.66M over the twelve months to Jul 31, 2026. Operating income fell 137.9% to -$1.02M, moving the operating margin from 4.7% to -1.7%. Free cash flow was -$6.14M, down 184.8% from a year earlier.
Revenue
$60.66M
+6.7% vs. a year earlier
Operating income
-$1.02M
-137.9% vs. a year earlier
Free cash flow
-$6.14M
-184.8% vs. a year earlier
EPS, diluted
-$0.08
-140.0% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jul 31, 2026
Valuation
- Market cap
- $65.18M
- P/E ratio
- –
- Price to sales
- 1.07
- Price to book
- 16.74
- Dividend yield
- –
- Free cash flow yield
- -9.42%
Fundamentals
- Revenue
- $60.66M
- Net income
- -$1.10M
- EPS, diluted
- -$0.08
- Free cash flow
- -$6.14M
- Book value per share
- $0.28
- Diluted shares
- 14M
Fifteen years at a glance
Fiscal years 2012 to 2026 and trailing twelve months, USD
Revenue
$60.66M+6.7% YoY
Gross profit
$30.22M+9.6% YoY
Operating income
-$1.02M-137.9% YoY
Net income
-$1.10M-137.8% YoY
EPS, diluted
-$0.08-140.0% YoY
Free cash flow
-$6.14M-184.8% YoY
Reported periodTrailing twelve months